

## Herantis Pharma to participate in upcoming November investor conferences

Herantis Pharma Plc, Press Release, 7 November 2022 at 09:00 A.M. EEST

**Herantis Pharma Plc (“Herantis”)**, developing disease modifying therapies for Parkinson’s disease, today announced that the company will participate in the following upcoming investor conferences:

### **Helsinki Sijoittajamessut (The Investor Fair 2022)**

Date: November 16, 2022

Location: Messukeskus Expo Centre, Helsinki, Finland

### **Carlsquare Life Science Investor Day**

Date: November 17, 2022

Location: Stockholm, Sweden

### **Redeye Life Science Day**

Date: November 24, 2022

Location: Stockholm, Sweden

If you are interested in scheduling a 1-on-1 meeting with Herantis management you can contact the conference organizers or connect with us at [ir@herantis.com](mailto:ir@herantis.com).

### **For more information, please contact:**

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: [ir@herantis.com](mailto:ir@herantis.com)

**Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400**

**Company website: [www.herantis.com](http://www.herantis.com)**

### **About Herantis Pharma Plc**

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDFN protein. It combines the compelling mechanism of action of the CDFN protein with the convenience of subcutaneous administration.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit [www.herantis.com](http://www.herantis.com)